Oaktree Capital Management Archives - Page 2 of 6

RBC Capital Markets Leads Syndicate Providing $200MM in Financing to Itafos

Itafos entered into credit facilities with a syndicate of lenders led by RBC Capital Markets, pursuant to which the lenders have advanced an $85 million term loan to the company and made available a $35 million letter of credit facility and an $80 million asset-based revolving credit facility.

Oaktree Capital Management Provides $225MM Credit Facility to Establishment Labs

Establishment Labs, a medical technology company focused on women’s health initially in the breast aesthetics and reconstruction market, entered into a $225 million term loan financing facility with funds managed by Oaktree Capital Management.

April 27, 2022 Aman Kumar | Cowen | Establishment Labs | Oaktree Capital Management | Raj Denhoy Ian Koplin

Oaktree Capital Management Provides $30MM in Funding to Marinus Pharmaceuticals

Marinus Pharmaceuticals, a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, received $30 million in funding under its existing credit agreement with Oaktree Capital Management.

April 1, 2022 Marinus Pharmaceuticals | Oaktree Capital Management Ian Koplin

Oaktree Capital Management Provides $100MM in Financing to Impel Neuropharma

Oaktree Capital Management closed two separate transactions totaling $100 million in gross funding for Impel NeuroPharma, a commercial-stage pharmaceutical company. The transactions include $50 million of senior secured debt.

March 18, 2022 Adrian Adams | Aman Kumar | Impel NeuroPharma | Oaktree Capital Management Phil Neuffer

Oaktree Capital Management Amends $150MM Term Loan with NN

NN, a diversified industrial company, amended its five-and-a-half-year, $150 million term loan with funds managed by Oaktree Capital Management.

March 7, 2022 Mike Felcher | NN | Oaktree Capital Management | Warren Veltman Ian Koplin

Oaktree Capital Management Provides Debt Refinancing to Innocoll

Innocoll Biotherapeutics, a specialty pharmaceutical company and portfolio business of Gurnet Point Capital, successfully refinanced its existing term loan facility with a $125 million term loan provided by funds managed by Oaktree Capital Management.

January 31, 2022 Aman Kumar | Gurnet Point Capital | Innocoll Biotherapeutics | Louis Pascarella | Oaktree Capital Management Ian Koplin

Oaktree Capital Management Acquires Velocity Risk Underwriters

Funds managed by Oaktree Capital Management, a global investment manager specializing in alternative investments, acquired Velocity Risk Underwriters, a catastrophe-focused property and specialty insurance risk managing general agent.

Ares, Oaktree and Diameter Provide Capital Injection to Vmo Aircraft Leasing

Vmo Aircraft Leasing increased its capital base from $500 million to $1.1 billion through its latest round of fundraising. Ares Alternative Credit Group, funds managed by Oaktree Capital Management and Diameter Capital Partners provided the capital injection.

U.S. Bankruptcy Court Approves Garrett Motion’s Plan of Reorganization

The U.S. Bankruptcy Court for the Southern District of New York confirmed Garrett Motion’s plan of reorganization, positioning the company to complete the implementation of the plan, which will be led by funds managed by Centerbridge Partners and Oaktree Capital Management.

JPMorgan, Oaktree, Morgan Stanley Complete New $265MM Financing for NN

NN completed a new financing with J.P. Morgan, Oaktree Capital Management and Morgan Stanley Tactical Value to provide a $50 million asset-based credit line, a $150 million term loan and a $65 million preferred stock issuance, respectively.

Tag Archives: Oaktree Capital Management